Click here for LIPOSORBER Instructions for Use and safety information
Find Treatment Center

LIPOSORBER® Provides Hope When Drug Therapy Fails™

LIPOSORBER is an extracorporeal therapy that enables patients to attain the recommended therapeutic targets when diet and maximum drug therapies have failed or are not tolerated. LIPOSORBER is shown to acutely reduce harmful cholesterol agents: Low-Density Lipoprotein Cholesterol (LDL-C), Lipoprotein(a) [Lp(a)].1

"What to Expect" Patient Videos, Now Available!

Empower Your Patients. Support Their Journey. We’re excited to share two new video resources on “What to Expect When Starting LIPOSORBER Treatment” – one targeting the adult audience and the other for pediatrics. These short, patient-friendly videos will walk your patient through the therapy experience, step-by-step, showing what treatment day will be like, answer questions, and help patients feel calm and ready.

READ MORE

Mary N. – Familial Hypercholesterolemia (FH) Patient Story

Cardiovascular Disease

Treatment with LIPOSORBER can help Familial Hypercholesterolemia (FH) patients reduce coronary events
by 72%.2*

Learn More about Cardiovascular Disease

Kidney Disease

Treatment with LIPOSORBER has enabled nearly 50% of steroid-resistant primary FSGS patients to attain complete or partial remission.3**

Learn More about Kidney Disease

Locate a Treatment Center Near You

LIPOSORBER® has more than 50 treatment locations throughout the country.
Locations

Are you a candidate for LIPOSORBER® Therapy?

LIPOSORBER is an FDA approved device that removes low-density lipoprotein cholesterol (LDL-C) and Lipoprotein(a) [Lp(a)] from the blood. Approximately 600,000 treatments have been performed worldwide on over 6,000 patients. Talk to your doctor about whether LIPOSORBER is right for you. Click below to take our quiz and discuss with your doctor.

FH Quiz
FSGS Quiz

References

  1. Kaneka Medical America LLC.,2025 LIPOSORBER LA-15 Instructions for use in Familial Hypercholesterolemia (FH).
  2. Mabuchi, H et al. “Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia.” Hokuriku-FH-LDL-Apheresis Study Group. The American journal of cardiology vol. 82,12 (1998): 1489-95. doi:10.1016/s0002-9149(98)00692-4.
  3. Muso, Eri et al. “Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study.” Clinical and experimental nephrology vol. 19,3 (2015): 379-86. doi:10.1007/s10157-014-0996-8.

*Serum lipid levels and outcomes in each treatment group were compared after approximately 6 years.

**Based on study that took place over two (2) years.